Susana Bandarra
Research Subjects
Research Interests
Susana Bandarra has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Paulo Mascarenhas
Aging Lab, Egas Moniz Center for Interdisciplinary Research (CiiEM), Egas Moniz School of Health & Science, Caparica, 2829-511 Almada, Portugal
8 shared publications - Isabel Barahona
Professor, Centro de Investigação interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz, Caparica, Portugal
7 shared publications Ana Clara Ribeiro
Centro de investigação interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz, Quinta da Granja, Caparica, Portugal
5 shared publicationsIsabel Barahona
Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Egas Moniz Cooperativa de Ensino Superior, Caparica, Portugal
5 shared publications- Ana Clara Ribeiro
Molecular Biology Laboratory, Egas Moniz Center for Interdisciplinary Research (CiiEM) Egas Moniz University Institute, Quinta da Granja, Monte da Caparica, 2829-511 Caparica, Portugal
3 shared publications Evguenia Bekman
Laboratório de Biologia Molecular, Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz, Quinta da Granja, Monte da Caparica, 2829-511 Caparica, Portugal
3 shared publications
Latest Publications
- Open Access
- 14 August 2023
- Published by MDPI AG in Medical Sciences Forum
- Vol. 22 (1) , 28
Performance of ID NOW Influenza A&B 2
ID NOW™ INFLUENZA A&B 2 is a point-of-care assay for rapid molecular diagnosis of Influenza A and B. The present study aims to evaluate the performance of ID NOW™ INFLUENZA A&B 2 compared to a reference RT-PCR assay. A total of 67 nasopharyngeal swabs from 67 patients for screening of Influenza A and B by RT-PCR (Allplex™ RP1) were also tested with ID NOW assay. Of the seventeen positive Influenza A and five positive Influenza B, fifteen (88%) and five (100%), respectively, were also detected by the ID NOW assay. The overall agreement with the reference test was 95.5%. The sensitivity was 88.2% for Influenza type A and 100% for Influenza type B, and the specificity was equal to or higher than 96% for both.
- 14 August 2023
- Published by MDPI AG in Medical Sciences Forum
- Vol. 22 (1) , 28
Open AccessPerformance of ID NOW Influenza A&B 2
ID NOW™ INFLUENZA A&B 2 is a point-of-care assay for rapid molecular diagnosis of Influenza A and B. The present study aims to evaluate the performance of ID NOW™ INFLUENZA A&B 2 compared to a reference RT-PCR assay. A total of 67 nasopharyngeal swabs from 67 patients for screening of Influenza A and B by RT-PCR (Allplex™ RP1) were also tested with ID NOW assay. Of the seventeen positive Influenza A and five positive Influenza B, fifteen (88%) and five (100%), respectively, were also detected by the ID NOW assay. The overall agreement with the reference test was 95.5%. The sensitivity was 88.2% for Influenza type A and 100% for Influenza type B, and the specificity was equal to or higher than 96% for both.
- Open Access
- 9 August 2023
- Published by MDPI AG in Medical Sciences Forum
- Vol. 22 (1) , 13
ID NOW: A NAAT System Solution for the Rapid and Accurate Detection of SARS-CoV-2 with VTM Sampling
ID NOW™ COVID-19 is a rapid molecular test for the detection of SARS-CoV-2. According to its instructions for use, this point-of-care test should be performed on dry nasopharyngeal swab (NPS) specimens. However, this method completely consumes the swab, with the limitation that additional analyses cannot be performed if required. The aim of this work was to evaluate the analytical performance of the ID NOW™ COVID-19 using NPS sampled on a viral transport medium. When compared to a reference RT-PCR, the positive and negative percent agreement was 86% and 100%, respectively. False negatives were associated with high RT-PCR Ct values.
- 9 August 2023
- Published by MDPI AG in Medical Sciences Forum
- Vol. 22 (1) , 13
Open AccessID NOW: A NAAT System Solution for the Rapid and Accurate Detection of SARS-CoV-2 with VTM Sampling
ID NOW™ COVID-19 is a rapid molecular test for the detection of SARS-CoV-2. According to its instructions for use, this point-of-care test should be performed on dry nasopharyngeal swab (NPS) specimens. However, this method completely consumes the swab, with the limitation that additional analyses cannot be performed if required. The aim of this work was to evaluate the analytical performance of the ID NOW™ COVID-19 using NPS sampled on a viral transport medium. When compared to a reference RT-PCR, the positive and negative percent agreement was 86% and 100%, respectively. False negatives were associated with high RT-PCR Ct values.
- 9 November 2021
- Published by American Society for Microbiology in Journal of Virology
- Vol. 95 (23)
APOBEC3B Potently Restricts HIV-2 but Not HIV-1 in a Vif-Dependent Manner
Primate lentiviruses encode a series of accessory genes that facilitate virus adaptation to its host. Among those, the vif -encoded protein functions primarily by targeting the APOBEC3 (A3) family of cytidine deaminases.
- 9 November 2021
- Published by American Society for Microbiology in Journal of Virology
- Vol. 95 (23)
APOBEC3B Potently Restricts HIV-2 but Not HIV-1 in a Vif-Dependent Manner
Primate lentiviruses encode a series of accessory genes that facilitate virus adaptation to its host. Among those, the vif -encoded protein functions primarily by targeting the APOBEC3 (A3) family of cytidine deaminases.
- Open Access
- 28 September 2021
- Published by Taylor & Francis in Annals of Medicine
- Vol. 53 (sup1) , S114-S115
Cytotoxicity of temperature-responsive cationic diblock copolymers in human cancer and non-cancer cells lines
Thermoresponsive polymers have been widely investigated in modern drug delivery and gene delivery systems, due to their potential to load and release the payload by simply modifying local temperatu...
- 28 September 2021
- Published by Taylor & Francis in Annals of Medicine
- Vol. 53 (sup1) , S114-S115
Open AccessCytotoxicity of temperature-responsive cationic diblock copolymers in human cancer and non-cancer cells lines
Thermoresponsive polymers have been widely investigated in modern drug delivery and gene delivery systems, due to their potential to load and release the payload by simply modifying local temperatu...
- Open Access
- 28 September 2021
- Published by Taylor & Francis in Annals of Medicine
- Vol. 53 (sup1) , S92-S93
Effect of Vif in doxorubicin treated breast cancer cells
Several studies linked DNA cytosine deaminase APOBEC3 to mutational process driving carcinogenesis [1]. However, APOBEC3 expression varies in breast cancer cells [2] and their role in breast cancer...
- 28 September 2021
- Published by Taylor & Francis in Annals of Medicine
- Vol. 53 (sup1) , S92-S93
Open AccessEffect of Vif in doxorubicin treated breast cancer cells
Several studies linked DNA cytosine deaminase APOBEC3 to mutational process driving carcinogenesis [1]. However, APOBEC3 expression varies in breast cancer cells [2] and their role in breast cancer...
- Open Access
- 22 July 2021
- Published by MDPI AG in Medical Sciences Forum
- Vol. 5 (1) , 39
Detection of the SARS-CoV-2 UK Variant in Portugal
At the end of 2020, a new highly transmissible variant of SARS-CoV-2 was discovered in the United Kingdom (UK). This work aims to identify potential cases of the UK variant in Portugal using routine diagnostic samples. A total of 26 out of 43 positive samples that were identified by RT-PCR as suspects were confirmed through sequencing to be the SARS-CoV-2 UK variant. The first case of the UK variant identified by us was in samples collected on 21 December 2020 at Lisbon airport in travelers from Manchester and London.
- 22 July 2021
- Published by MDPI AG in Medical Sciences Forum
- Vol. 5 (1) , 39
Open AccessDetection of the SARS-CoV-2 UK Variant in Portugal
At the end of 2020, a new highly transmissible variant of SARS-CoV-2 was discovered in the United Kingdom (UK). This work aims to identify potential cases of the UK variant in Portugal using routine diagnostic samples. A total of 26 out of 43 positive samples that were identified by RT-PCR as suspects were confirmed through sequencing to be the SARS-CoV-2 UK variant. The first case of the UK variant identified by us was in samples collected on 21 December 2020 at Lisbon airport in travelers from Manchester and London.
- Open Access
- 21 July 2021
- Published by MDPI AG in Medical Sciences Forum
- Vol. 5 (1) , 19
Characterization of CYP2C19*17 Polymorphism in a Portuguese Population Sample Relevant for Proton Pump Inhibitor Therapy—A Pilot Study
The interindividual variability of Proton Pump Inhibitor (PPI) therapy results from the phenotype variability associated with the cytochrome P450 2C19 (CYP2C19) gene, namely the CYP2C19*17 allele. Our aim was to characterize patients’ genetic variability undergoing PPI therapy. A sample of 33 oral mucosa cells from Portuguese pharmacy patients was collected, followed by genotyping. The allelic frequencies of CYP2C19*1 (-806C) and CYP2C19*17 (-806T) were 71.2% and 28.8%, respectively. The genotypic frequencies for CYP2C19*1/*1 and CYP2C19*1/*17 were 42.4% and 57.6%, respectively, and 19 of these patients may have a Rapid Metabolizer (RM) phenotype pharmaceutical opinion letter, based on genetic evidence.
- 21 July 2021
- Published by MDPI AG in Medical Sciences Forum
- Vol. 5 (1) , 19
Open AccessCharacterization of CYP2C19*17 Polymorphism in a Portuguese Population Sample Relevant for Proton Pump Inhibitor Therapy—A Pilot Study
The interindividual variability of Proton Pump Inhibitor (PPI) therapy results from the phenotype variability associated with the cytochrome P450 2C19 (CYP2C19) gene, namely the CYP2C19*17 allele. Our aim was to characterize patients’ genetic variability undergoing PPI therapy. A sample of 33 oral mucosa cells from Portuguese pharmacy patients was collected, followed by genotyping. The allelic frequencies of CYP2C19*1 (-806C) and CYP2C19*17 (-806T) were 71.2% and 28.8%, respectively. The genotypic frequencies for CYP2C19*1/*1 and CYP2C19*1/*17 were 42.4% and 57.6%, respectively, and 19 of these patients may have a Rapid Metabolizer (RM) phenotype pharmaceutical opinion letter, based on genetic evidence.
- Open Access
- 11 July 2021
- Published by MDPI AG in Medical Sciences Forum
- Vol. 5 (1) , 7
Evaluation of the Cytotoxic Potential of Adhesives, with Two on the Market: Scotchbond Universal and Optibond Solo Plus, and an Adhesive in the Experimental Phase: T1
In vitro studies evaluating the cytotoxic potential of substances released from dental adhesives are lacking. The purpose of this study was to compare the cytotoxicity of the extracts of dental adhesives Scotchbond Universal and Optibond Solo Plus, and an adhesive in the experimental phase: T1. 3T3 mouse fibroblast cells and MG-63 osteoblast-like cells from human osteosarcoma were exposed for 24 h to serial extract dilutions. Cytotoxicity was determined using an MTT assay. For both cell lines, the cytotoxicity order obtained, of the unfiltered adhesive extracts, was T1 (less cytotoxic) < Optibond Solo Plus < Scotchbond Universal (most cytotoxic).
- 11 July 2021
- Published by MDPI AG in Medical Sciences Forum
- Vol. 5 (1) , 7
Open AccessEvaluation of the Cytotoxic Potential of Adhesives, with Two on the Market: Scotchbond Universal and Optibond Solo Plus, and an Adhesive in the Experimental Phase: T1
In vitro studies evaluating the cytotoxic potential of substances released from dental adhesives are lacking. The purpose of this study was to compare the cytotoxicity of the extracts of dental adhesives Scotchbond Universal and Optibond Solo Plus, and an adhesive in the experimental phase: T1. 3T3 mouse fibroblast cells and MG-63 osteoblast-like cells from human osteosarcoma were exposed for 24 h to serial extract dilutions. Cytotoxicity was determined using an MTT assay. For both cell lines, the cytotoxicity order obtained, of the unfiltered adhesive extracts, was T1 (less cytotoxic) < Optibond Solo Plus < Scotchbond Universal (most cytotoxic).
- 1 April 2021
- Published by Elsevier in The Journal of Prosthetic Dentistry
- Vol. 125 (4) , 705.e1-705.e7
Biocompatibility of self-adhesive resin cement with fibroblast cells
- 1 April 2021
- Published by Elsevier in The Journal of Prosthetic Dentistry
- Vol. 125 (4) , 705.e1-705.e7
Biocompatibility of self-adhesive resin cement with fibroblast cells
- 1 March 2020
- Published by Elsevier in Dental Materials
- Vol. 36 (3) , 442-455
Suitability of 3D printed pieces of nanocrystalline zirconia for dental applications
- 1 March 2020
- Published by Elsevier in Dental Materials
- Vol. 36 (3) , 442-455
Suitability of 3D printed pieces of nanocrystalline zirconia for dental applications